Accuray cyberknife® and tomotherapy® platforms featured in more than 55 abstracts presented at estro 2023, reinforcing systems' versatility, efficiency and effectiveness

Data highlight expanding use of (ultra) hypofractionated treatments, benefits in patient care made possible by the precision and accuracy of accuray technologies sunnyvale, calif. , may 17, 2023 /prnewswire/ -- accuray incorporated (nasdaq: aray) announced today that new data presented at the european society for radiotherapy and oncology (estro) meeting reinforces the benefits of the company's cyberknife ® and tomotherapy ® platforms, including the latest generation radixact ® system.
ARAY Ratings Summary
ARAY Quant Ranking